ADAM9 and neoplasm: Most tumour types that were included were rare and their genomic landscape has been essentially unexplored, so the genomic profiles of these tumours revealed useful therapeutic and etiological information, e.g. novel ADAM9-BRAF fusion, genomic algorithms, HRD without a DNA mismatch repair gene mutation and viral insertions.